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Introductlon
Venous thromboembolism is a major cause of morbidity and
mortality with an incidence of about l per 1000 per year.
Predisposing factors can be either environmental or genetic.
The first include trauma, surgery, immobilization, obesity,
oral contraceptives, pregnancy and puerperium. The second
included until recently a few rare hereditary disorders of blood
coagulation (antithrombin, protein C and protein S deficiency).
Together these genetic defects can be found in about 15% of
selected patients with a personal and/or family history of
thrombo-embolic disease (1-5) and only in a few percent of all
patients with venous thrombosis (5,6).
Recently the Situation changed dramatically by the discovery
of a novel genetic defect associated with thrombophilia (7-10).
In 1993 Dahlback et al. reported three families where the
laboratory fmding of resistance to activated protein C (APC)
cosegregates with the thrombophilia (7). They proposed that
hereditary APC-resistance is an autosomal dominant disorder.
Subsequent studies revealed that APC-resistance is a common
finding in patients with venous thrombosis (8,9,11,12) and is
almost always caused by one mutation in the factor V gene (l691
G -> A, numbering according to ref.13) which will destroy
one of the APC-cleavage sites in factor V by the replacement of
Arg-506 by Gin (10,14,15). With the discovery of this new
genetic risk factor for thrombosis a major step forward was made
Table 1. Prevalence of genetic defects in (familial) thrombophilia.
Prevalences have been calculated from data reported by Briet et al. (1),
Gladson et al. (2), Ben Tal et al. (7), Tabernero et al. (4) and Pabinger
et al. (5). The figure for the prevalence of APC resistance refers to
our own observations. Three to four percent of the patients have
APC-resistance in combination with one of the other genetic defects.
The number of different mutations was derived from recentrevisions of
the respective mutation databases.
Genetic defect Prevalence (%) No of different
mutations
Dysfibrinogenemia
Antithrombin deficiency
Protein C deficiency
Protein S deficiency
APC-resistance
Unknown
1.0
4.2
4.9
5.1
46
42
>11
>79
>160
>13
1
?
in our understanding of the clustering of thrombophilia in selected
families (see Table 1). Especially the fact that in contrast to
hereditary protein C, protein S and antithrombin deficiency,
hereditary APC-resistance is a very common disorder which is
caused almost exclusively by one single gene mutation, has
contributed to establishing the concept of venous thrombosis äs
a multifactorial disease.
Laboratory diagnosis of APC-resistance
In their original article Dahlback et al described three different
tests that can be used for the analy sis of the response of a patient' s
plasma to the anticoagulant action of activated protein C (7).
Although the test principle in itself was not new (16-19) and had
been usedpreviously for the identification of plasma components
that might interfere with the expression of the APC anticoagulant
activity (20), the authors were the first to introduce such a test for
the study of familial thrombophilia and for the screening of
patients with thrombosis. Many modifications of this test or
alternative test procedures have been developed (21-27) and
used for screening purposes. The question now arises whether
all these different tests will identify the same individuals äs
APC-resistant.
Most tests rely on the measurement of two APTT's, one in
the presence of APC and one in its absence, whereas the
test result is expressed äs an APC sensitivity ratio
[APC-SR:APTT (+APC)/APTT(-APC)] or a normalized APC-
SR (n-APC-SR:APC-SRpalicn/ APC-SRPNP) (7,21,25). However,
even after standardization of the test and analysis of the optimal
pre-analytical conditions, tests may differ with respect to their
sensitivity and specificity in detecting the factor V mutation.
Moreover tests will differ also in their sensitivity for acquired
defects like lupus anticoagulant (28,29), reduced prothrombin
and factor X (25) and elevated factor VIII (23). Also the
Performance of the test - like that of the APTT itself - might
depend on the actual Instrument used (26). Finally, the fact that
APC-resistance is a rather common finding in the general
Population (9,10), will make it necessary to rely on statistical and
therefore somewhat arbitrary diagnostic criteria (9,25). All these
considerations support the notion that it is not seifevident that the
results obtained in one laboratory with one specific test can be
reproduced in other laboratories using different tests.
Mailing address:
'Haemostasis and Thrombosis Research Center
Bldg. l C2-R, University Hospital Leiden
P.O. Box 9600, 2300 RC Leiden, The Netherlands
Fax (31)71 225555
Factor V Leiden
Previously we reported that 80% of the individuals that fulfilled
our statistical criteria for APC-resistance (n-APC-SR <0.84
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with the local lest) were found to be heterozy gous or homozy gous
for the: 1691G ->A Substitution in exon 10 of the factor V gene,
whereas all carriers of the mutation were APC-resistant
(n-APC-SR <0.84) (10). The mutation predicts the replacement
of Arg506 by Gin in one of the APC-cleavage sites of the heavy
chain of factor V. It will reduce the rate of the inactivation of
thrombin activated factor V by APC (10,30,31) thereby promoting
procoagulant activity of factor V. This might explain why
carriers of the mutation have an increased risk for thrombosis (see
also below).
An interesting question is whether the factor V mutation will
explain all cases of APC-resistance or whether we still should
continue our hunt for other mutations. In Table 2 we have
summarized the data from a large patient control study (see also
Fig. 1). In total 894 individuals (422 patietns and 472 controls)
were screened for the presence of APC resistance and factor V
mutation. It appears that 95 of the 97 individuals with a n-APC-
SR <0.70 (äs measured with our local test) are carries of the
factor V mutation and none of the 797 individuals with a
n-APC-SR >0.70 (see also ref. 32). The latter group includes 57
individuals with a ratio between 0.70 and 0.84, that all fulfill our
criterium for APC-resistance (n-APC-SR <0.84). Family studies,
that were performed for some of these individuals, did not
provide any evidence for an inherited defect (9). Further analysis
of these individuals should help us to decide whether we should
adjust our criteria for APC-resistance or whether we should
consider this group of individuals äs carriers of other genetic or
acquired defects.
Table 2. Genetic heterogeneity of APC resistance. n-APC-SR and the
genotype of nt 1691 in exon 10 of the factor V gene were determined
for all patients and controls from the Leiden Thrombophilia Study
(cfr. ref. 9) äs previously described (9,10,25). Both parameters were
available for 422 patients (Np) and 472 controls (Nc).
n-APC-SR Np Nc Genotype (nt 1691)
GG AG AA
>0.84
0.70-0.84
0.50-0.70
<0.50
298
41
74
9
442
16
14
0
740
57
2
—
—
86
1
,
—
—8
Also data from other laboratories suggest that the large
majority of APC-resistant individuals is carrier of the factor V
mutation (30,32,33,35,36) butthat notall casesof APC-resistance
are explained by the mutation (15,33,34). Recently Zöller et al.
(37) reported that 29 out of 33 index cases with APC-resistance
(APC-SR <2.0) did carry the factor V mutation. However, with
the APC-resistance test used in their laboratory, a relatively large
percentage of the heterozygous carriers of the factor V mutation,
have APC-SR's in the ränge observed for non carriers of the
mutation. Similarly, fifteen percent of the non-carriers have
APC-SR's in the ränge of heterozygous carriers of the mutation.
This suggests that their test is less specific in identifying carriers
of the factor V mutation, but possibly more sensitive to other äs
yet unknown acquired or genetic defects. This might explain
some of the apparent conflicts recently reported in the literature
(see above).
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Fig. l · n-APC-SR and factor V genotype in patients and controls from
the Leiden Thrombophilia Study .0 heterozy gous for the factor V Leiden
mutation (1691 AG)· homozygous for the factor V Leiden mutation
(1691 AA) Ohomozygous normal (1691 GG). Arrows indicate two
patients with a n-APC-SR between 0.50 and 0.70 who do not carry
the FV mutation and have a lupus anticoagulant and one patient with a
n-APC-DR <0.50 who is heterozygous for the FV mutation.
APC-resistance äs risk factor for thrombosis
The first indication that APC-resistance might be associated with
an increased risk for thrombosis came from observations in
families with thrombophilia (7,12) and groups of selected patients
with idiopathic or familial thrombosis (8). Formal evidence for
this association came from the analysis of the data obtained in a
large population based patient-control study:the Leiden
Thrombophilia Study (LETS) (9). In this study 474 consecutive
patients with a first episode of objectively confirmed deep vein
thrombosis and 474 age and sex matched healthy controls were
included. From the analysis of the results of the APC-SR
measurements in the first 301 patients and controls it was
concluded that 21% of the patients and 5 % of the healthy controls
had an APC-SR <2.17 with the local test. This leads to an
estimated seven fold increase in risk of deep-vein thrombosis
(matched odds ratio 6.6; 95% (CI 3.6-12.0). In the meantime
APC-SR's and the factor V genotype have been measured in all
patients and controls. Both parameters were available for 472
controls and 422 patients (49 patients were on oral anticoagulants
and for five individuals one of the parameters was missing). The
data are shown in Fig. l. Twenty eight percent of the patients and
only 5.7% of the controls have a n-APC-SR <0.84, confirming
that having an APC-SR <0.84 is a risk factor for thrombosis (9).
From the 97 individuals with an n-APC-SR <0.70, 95 were
carrier of the FV mutation while 2 had a low n-APC-SR associated
with the presence of lupus anticoagulant (see also 28,29). It is
interesting to note that even when we omit all carriers of the factor
V mutation the mean n-APC-SR for patients is lower than for the
controls. The reason for this is not known. It might reflect a
post-thrombotic effect on the n-APC-SR or point to a second
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unidentified risk factor for thrombosis which affects the response
of plasma to activated protein C.
Frequencies of APC resistance in cohorts of thrombosis
patientsdepending on patients selectivity criteria, ränge from
17.5% to 64% (879,11,12,21,38-40). Prevalence of APC
resistance in controls was reported to be from 2% to 7% (9,11,35).
One should keep in mind that in these studies different tests and
criteria for APC resistance have been used.
Factor V Leiden äs risk factor for thrombosis
The evidence that factor V Leiden is a risk factor for thrombosis
again comes from the aforementioned patient-control study (41).
After genotyping of all patients and controls it was calculated that
the relative risk of thrombosis is 7.9 (CI95:4.1-13.0) in
heterozygous carriers of the defect. In homozygous camers the
relative risk was estimated to be 91 (CI95:26-322) using the
assumption of complete Hardy Weinberg equilibrium for the
Factor V mutation in the control group. The median age of onset
of Symptoms was 44 (ränge 17-69) in heterozygotes and 31
(ränge 22-55) in homozygotes (41). In general the relative risks
were found to be independent of age. Given that the risk of
thrombosis increases with age this indicates a higher incidence of
thrombosis in carriers of the mutation in the older age groups.
Additional information on the risk of thrombosis in carriers of
the factor V mutation comes from the study of relatives of
symptomatic patients who carry the mutation (37). Zöller et al.
(37) studied 50 Swedish thrombophilic families with inherited
APC resistance. In the 47 families, where the factor V mutation
was segregating, they observed that the cumulative penetranceof
thrombosis was 44% in homozygotes for the factor V mutation,
30% in heterozygotes and 10% in homozygous normals. These
figures clearly indicate that in these families the factor V Leiden
mutation is a risk factor for thrombosis. Whether similar
results will be obtained in families identified through an
asymptomatic carrier of the factor V mutation needs to be
established in the future.
Interaction of factor V Leiden with other genetic risk
factors for thrombosis
During the past twenty years the study of familial thrombophilia
has been focussed mainly on the identification of single genetic
defects that could explain the segregation of the thrombophilia in
affected families. The concept underlying this approach is that
familial thrombophilia is a single gene disorder. The notion that
this view might be too simple has been expressed repeatedly
during the last years especially in relation to the observations in
protein C deficient families (42,43). Data coming from patient
control studies clearly indicate that protein C deficiency is a risk
factor for thrombosis (6,44). So it is not surprising that in families
of symptomatic probands a significant association between
thrombophilia and protein C deficiency is observed (45^t7),
although the penetrance of the disease is variable and incomplete
(clinically dominant protein C deficiency). In contrast, it was
surprising that the prevalence of protein C deficiency among
healthy blood donors is much higher than expected (48,49) and
that thrombosis is a very rare observation in these protein C
deficient families (clinically recessive protein C deficiency).
Together these observations have led to the hypothesis that in
clinically dominant protein C deficient families the segregation
of other genetic risk factors might contribute to the phenotype of
thrombophilia (42,43).
Support for this hypothesis, however, was difficult to find.
Because the prevalence of protein C, protein S and antithrombin
deficiency is rather low, families where two or more of these
genetic defects segregate are extremely rare (5). This Situation
changed with the recent discovery of factor V Leiden äs risk
factor for thrombosis. The factor V mutation is found in 3-4% of
the population and ten times more common than all the other
genetic risk factors together (14,36,41). This finding made it
possible for the first time to lest the concept that familial
thrombophilia might be a multiple gene disorder.
The first support for this concept came from a study of
Koeleman et al. (50). They reported that 19% of 48 unrelated
symptomatic protein C deficient probands from thrombophilic
families is also carrier of the factor V Leiden mutation. In 6
families where both the factor V mutation and a protein C gene
mutation are segregating, the penetrance of thrombophilia is
significantly higher in carriers of both gene defects (73%) than in
carriers of a single gene defect (36% and 10%). This is also
illustrated in Fig. 2 where the thrombosis free survival curves
have been plotted for those carrying two gene defects, only one
gene defect or no gene defect. These results indicate that in these
families carriers of both gene defects have an increased risk for
thrombosis compared with siblings with a single defective gene.
The high prevalence of the factor V mutation among symptomatic
1 UU ~
"5
Έ 0.75-
ai
"^  0.50-
JD
0
£ 025-
i, h...^
(
·,1 ,
··-,
 L
-- — i
S LL ,
1 ,
i
i
i ,
i
i
20 30 40 50 60 70 80 90
Age ( years )
Fig. 2. Thrombosis free survival curves for family members carrying
both the factor V mutation and a protein C gene mutation (- ), for
family members carrying only one gene mutation ( ) and for those
relatives who carry no gene mutation (—).
protein C deficient probands might be related to the fact that most
of these families have been selected because of clustering of
thrombophilia. When werepeat the analysis in a panel of unselected
symptomatic protein C deficientpatients from the aforementioned
patient control study (44), the frequency of the factor V mutation
is much lower (0/13). So selection for familial thrombophilia
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is important for fmding these combmed deficiencies. This
might explain some of the apparently conflicting data in the
hterature(8,51).
We have found that the factor V mutation can also be found
frequently in famihes with famihal thrombophiha and other
geneüc defects:l/12 patients with dysfibnnogenaemia, 3/11
patients with antithrombin deficiency and 6/16 patients with
protein S deficiency (unpubhshed observations).
All these findmgs Support the concept that famihal
thrombophiha is a multiple gene disorder The observation that
the penetrance of thrombosis in patients with two gene defects is
higher than in those with a smgle gene defect will have important
imphcations for the chnical management of these individuals in
the future.
Interaction of factor V Leiden with environmental risk
factors for thrombosis
The high prevalence of the factor V mutation among patients with
deep vein thrombosis, also makes itpossible to study its mteraction
with common environmental nsk factors for thrombosis. For
instance the use of oral contraceptives is a well known, and much
debated nsk factor for venous thrombosis The question arises
whether the occurrence of thrombosis in oral contraceptive users
might be explamed by the factor V Leiden mutation. This
question was recently addressed by Vandenbroucke et al (52) in
areanalysisof datafrom 155 consecutivepremenopausal women
who had developed venous thrombosis and 169 population
controls (data denved from the larger case-control study). They
found that the nsk of thrombosis increased 3.8 fold among oral
contraceptive users (when compared to non users) and 8 fold
among factor V Leiden carners (when compared to non camers).
However m those who used oral contraceptives and were camer
of the factor V mutation, therisk of thrombosis was 35 fold higher
than in those not usmg oral contraceptives and not carrying the
factor V mutation By backcalculation of their data to population
incidence rates, the authors demonstrated that the combination of
the factor V mutation and oral contraceptive use gwes a larger
nsk difference than the sum of the individual effects (see
Table 2 m ref. 52). The nsk of thrombosis among women who
have both the factor V mutation and use oral contraceptives,
might indicate that both factors act on the same physiological
process. In this respect it is of interest that also in healthy women,
the use of oral contraceptives leads to a significant decrease in
APC-SR (53).
Future studies should define whether the presence of the
factor V mutation also will increase the sensitivity of individuals
for other estabhshed environmental nsk factors for thrombosis
like trauma, immobihzation, pregnancy and puerpenum.
Summary
The recent discovery of the factor V Leiden mutaüon äs the
moleculardefectinthelargemajontyofAPC-resistantindividuals,
has drasücally changed our view on famihal thrombophiha and
it has contnbuted to a better understanding of the mteraction of
geneüc and environmental nsk factors. It has offered firm support
for the view that venous thrombosis is a multifactonal disease
and that the nsk of thrombosis will increase äs the number of
geneüc and/or environmental nsk factors increases
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